Interleukin-23 Subunit p19
"Interleukin-23 Subunit p19" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A subunit of interleukin-23. It combines with INTERLEUKIN-12 SUBUNIT P40, which is shared between the two cytokines, to form in the active interleukin-23 cytokine.
| Descriptor ID |
D053760
|
| MeSH Number(s) |
D12.644.276.374.465.759.500 D12.776.467.374.465.759.500 D23.529.374.465.550.500
|
| Concept/Terms |
Interleukin-23 Subunit p19- Interleukin-23 Subunit p19
- Interleukin 23 Subunit p19
- Interleukin-23 alpha Subunit
- Interleukin 23 alpha Subunit
- alpha Subunit, Interleukin-23
- IL-23p19
- IL-23 p19
|
Below are MeSH descriptors whose meaning is more general than "Interleukin-23 Subunit p19".
Below are MeSH descriptors whose meaning is more specific than "Interleukin-23 Subunit p19".
This graph shows the total number of publications written about "Interleukin-23 Subunit p19" by people in this website by year, and whether "Interleukin-23 Subunit p19" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2017 | 1 | 0 | 1 |
| 2018 | 2 | 3 | 5 |
| 2019 | 1 | 0 | 1 |
| 2020 | 1 | 0 | 1 |
| 2021 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Interleukin-23 Subunit p19" by people in Profiles.
-
Bioinformatic analyses hinted at augmented T helper 17 cell differentiation and cytokine response as the central mechanism of COVID-19-associated Guillain-Barré syndrome. Cell Prolif. 2021 May; 54(5):e13024.
-
Can immunological manipulation defeat SARS-CoV-2? Why G-CSF induced neutrophil expansion is worth a clinical trial: G-CSF treatment against COVID-19. Bioessays. 2021 02; 43(2):e2000232.
-
The risk of respiratory tract infections in patients with psoriasis treated with interleukin 23 pathway-inhibiting biologics: A meta-estimate of pivotal trials relevant to decision making during the COVID-19 pandemic. J Am Acad Dermatol. 2020 11; 83(5):1523-1526.
-
The IL-23p19/EBI3 heterodimeric cytokine termed IL-39 remains a theoretical cytokine in man. Inflamm Res. 2019 Jun; 68(6):423-426.
-
Spondyloarthritis: new insights into clinical aspects, translational immunology and therapeutics. Curr Opin Rheumatol. 2018 09; 30(5):526-532.
-
Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study. Lancet Gastroenterol Hepatol. 2018 10; 3(10):671-680.
-
Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study. Ann Rheum Dis. 2018 09; 77(9):1295-1302.
-
Can IL-23 be a good target for ulcerative colitis? Best Pract Res Clin Gastroenterol. 2018 Feb - Apr; 32-33:95-102.
-
MPO Promoter Polymorphism rs2333227 Enhances Malignant Phenotypes of Colorectal Cancer by Altering the Binding Affinity of AP-2a. Cancer Res. 2018 05 15; 78(10):2760-2769.
-
Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study. Lancet. 2017 04 29; 389(10080):1699-1709.